FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Introduction and Objectives: OAB is common in older patients, as are comorbidities that can impact a patient's risk for experiencing AEs. Risk of AEs could also impact a physician’s OAB treatment decisions. Most antimuscarinic agents used in OAB treatment are nonselective and may have adverse cardiovascular (CV) and central nervous system (CNS) effects. Our study objective was to identify the proportion of OAB patients potentially at risk for AEs by assessing important comorbidities (focus on CV and CNS) and concomitant drug use (focus on drugs with known CNS effects). We also sought to assess the impact on OAB treatment decisions, by evaluating the presence of comorbidities and concomitant drug use among treated and untreated OAB patients.
Materials: Adult patients (age > 18) from the HealthCore Integrated Research (HIRD) database with a diagnosis of OAB (ICD9 codes: 596.51, 596.55, 596.59, 788.31) or a pharmacy claim between 1/1/2000 to 12/31/2006 for an OAB antimuscarinic agent (tolterodine, oxybutynin, trospium, solifenacin, or darifenacin), and with 12 months of continuous health plan eligibility, formed the OAB cohort. Based on the presence of at least 1 pharmacy claim for an OAB antimuscarinic agent, the OAB cohort was stratified as treated and untreated. A random sample of patients with neither a diagnosis of OAB, nor any urinary bladder dysfunction (ICD9 codes: 596.5x, 788.3x, 344.61, 625.6x), nor a pharmacy claim for an OAB antimuscarinic agent formed a comprehensive non-OAB control cohort. During the 12 months prior to OAB diagnosis/treatment, CV and CNS comorbidities and use of medications with known CNS effects (identified using a modified version of the revised Beers Criteria; excluding OAB antimuscarinic agents) were assessed across the treated OAB, untreated OAB, and non-OAB cohorts using t tests for continuous variables and chi-square tests for categorical variables.
Results: All OAB patients (N: 6,632; 83% women; median age: 51 years), when compared to non-OAB patients (N: 67,478; 83% women; median age: 48 years), were more likely to have CV (39% vs 18%; P < 0.0001) and CNS disorders (39% vs 16%; P < 0.0001), as well as prior exposure to medications with CNS effects (47% vs 25%; P < 0.0001). In treated vs untreated OAB pts (1:1 matched), CV comorbidities (40% vs 38%; P = 0.3259) and CNS comorbidities (39% vs 38%; P = 0.4194) did not differ. However, more treated patients had prior exposure to medications with CNS effects than the untreated patients (51% vs 43%; P < 0.0001).
Conclusions: A large proportion of OAB patients have pre-existing CV/CNS comorbidities and prior exposure to medications with CNS effects, and are significantly different from control patients without OAB. Lack of evidence that treated patients have fewer pre-existing CV/CNS comorbidities and less prior exposure to medications with CNS effects relative to untreated patients suggests that physicians do not take these factors into consideration prior to prescribing OAB antimuscarinic agents.